UnitedHealth CEO leaves abruptly, company pulls forecast as shares sink
Published on 05/13/2025 at 16:56

Market Closed -
Other stock markets
|
After hours 08:00:00 pm | |||
313.53 USD | -1.56% |
|
312.65 | -0.28% |
Jun. 13 | Health Care Losses Limited by Defensive Bias - Health Care Roundup | DJ |
Jun. 13 | Social Buzz: Wallstreetbets Stocks Decline Pre-Bell Friday; Tesla, Nvidia to Open Lower | MT |
Published on 05/13/2025 at 16:56
Andrew Philip Witty is a British businessperson who has been the head of 8 different companies. Presently, Sir Witty holds the position of Chief Executive Officer & Director at UnitedHealth Group, Inc. and Chief Executive Officer for InGensa, Inc. (a subsidiary of UnitedHealth Group, Inc.) and Chief Executive Officer of GlaxoSmithKline, Inc. Sir Witty is also on the board of Synthego Corp., Pharmaceutical Research & Manufacturers of America and G1 Therapeutics, Inc. and Chancellor at The University of Nottingham and Member of Business Council for Britain. In his past career Andrew Philip Witty held the position of Chief Executive Officer & Executive Director at GlaxoSmithKline Plc Chief Executive Officer & Director at Genelabs Technologies, Inc. Chief Executive Officer & Director at GlaxoSmithKline Australia Pty Ltd. Managing Director at GlaxoSmithKline South Africa (Pty) Ltd. Director-Pharmacy & Distribution at Glaxo Holdings Plc, Senior Vice President-Asia Pacific at GlaxoSmithKline Pte Ltd. Area Director at Glaxo Wellcome South Africa Pty Ltd. and Vice President & General Manager-Marketing at Glaxo Wellcome, Inc. (which are all subsidiaries of GlaxoSmithKline Plc), Director-Business Development at Biocompatibles International Ltd., Member-International Advisory Council at Singapore Economic Development Board and Chairman for European Federation of Pharmaceutical Industries & Assns. Sir Witty received an undergraduate degree from The University of Nottingham.
View full profileSelect your edition
All financial news and data tailored to specific country editions